At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 43 enrolled
Drug / intervention
MEDI-573drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Multicenter, Open-label, Single-arm, Dose-escalation Study to Evaluate the Safety, Tolerability, and Antitumor Activity of MEDI-573, a Fully Human Monoclonal Antibody Directed Against Insulin-like Growth Factors I and II, in Subjects With Advanced Solid Tumors Refractory to Standard Therapy or for Which No Standard Therapy Exists
In Brief
A Phase 1 clinical trial evaluating MEDI-573 for Cancer. Completed, enrolled 43 participants across 6 sites.
Detailed Summary
Evaluate the safety and tolerability of MEDI-573 in adult subjects with advanced solid tumors refractory to standard therapy or for which no standard therapy exists.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2009
Enrollment StartMar 2009
Primary CompletionSep 2012
TodayJul 2026
First PostedJan 1, 2009
Enrollment StartMar 9, 2009
Primary CompletionSep 11, 2012
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 17.5 years ago
Interventions
MEDI-573drug
Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.